Risk of lower limb amputation in diabetic patients using SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists: a meta-analysis of 2 million patients [0.03%]
钠-glucose协同转运蛋白2抑制剂与二肽基肽酶4抑制剂或胰高血糖素样肽-1受体激动剂相比降低糖尿病患者截肢风险的荟萃分析（涉及200万例患者）
Yang Lu,Caiyun Guo
Yang Lu
Background: The objective of this review was to assess the risk of lower limb amputation (LLA) in type 2 diabetic patients based on the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) versus dipeptidyl peptidase...
Serious neurological adverse events following immunization against SARS-CoV-2: a narrative review of the literature [0.03%]
有关SARS-CoV-2免疫接种后严重神经不良事件的文献综述性文章
Sara Eslait-Olaciregui,Kevin Llinás-Caballero,David Patiño-Manjarrés et al.
Sara Eslait-Olaciregui et al.
Amid the coronavirus disease 2019 (COVID-19) pandemic, massive immunization campaigns became the most promising public health measure. During clinical trials, certain neurological adverse effects following immunization (AEFIs) were observed...
Development and psychometric assessment of self-reported patient medication safety scale (SR-PMSS) [0.03%]
自我报告患者用药安全量表（SR-PMSS）的编制及检验研究
Ning Qin,Yinglong Duan,Shuangjiao Shi et al.
Ning Qin et al.
Objectives: Patient medication safety can affect their clinical outcomes and plays an important role in patient safety management. However, few tools have been developed to assess patient medication safety. This study aim...
Therapy of women with multiple sclerosis: an analysis of the use of drugs that may have adverse effects on the unborn child in the event of (unplanned) pregnancy [0.03%]
多发性硬化症妇女的治疗：分析可能对胎儿产生不良影响的药物的使用情况（计划外怀孕）
Marie-Celine Haker,Niklas Frahm,Michael Hecker et al.
Marie-Celine Haker et al.
Background: Although effective contraception is strongly recommended during the therapy of women with multiple sclerosis (MS) with some immunomodulatory drugs, unplanned pregnancies still occur. Adequate medication manage...
Impact of risk communication on patient's safety during the pandemic [0.03%]
疫情期间风险交流对患者安全的影响分析——基于英国的一项定性研究
Heyde-Patricia Zuluaga-Arias,Mayada Alkhakany,Manal M Younus et al.
Heyde-Patricia Zuluaga-Arias et al.
More than 2 years has passed since the pandemic was declared in 2019 due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was later declared to be the pathogen causing coronavirus disease 2019 (COVID-19). During th...
Analysis of the nature and contributory factors of medication safety incidents following hospital discharge using National Reporting and Learning System (NRLS) data from England and Wales: a multi-method study [0.03%]
基于英格兰和威尔士国家报告与学习系统数据的出院后用药安全事件的性质及影响因素的多方法研究分析
Fatema A Alqenae,Douglas Steinke,Andrew Carson-Stevens et al.
Fatema A Alqenae et al.
Introduction: Improving medication safety during transition of care is an international healthcare priority. While existing research reveals that medication-related incidents and associated harms may be common following h...
Developing and piloting a cross-sectoral hospital pharmacist intervention for patients in transition between hospital and general practice [0.03%]
一种跨部门的医院药剂师干预措施的研发与试点实施，用于住院和门诊之间转诊患者的治疗
Charlotte Arp Sørensen,Linda Jeffery,Jannik Falhof et al.
Charlotte Arp Sørensen et al.
Background: Healthcare is challenged by a rapidly growing group of patients with multi-morbidity and polypharmacy. Increasing activity and specialization puts pressure on healthcare sectors. Medication errors in cross-sec...
Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database [0.03%]
基于美国食品药品监督管理局不良事件报告系统数据库的质子泵抑制剂与横纹肌溶解风险关联性研究
Ali F Altebainawi,Lulwa A Alfaraj,Amjad A Alharbi et al.
Ali F Altebainawi et al.
Background: This research aims to explore and compare the signals of rhabdomyolysis from the use of Proton pump inhibitors (PPIs) using the United States Food and Drug Administration Adverse Event Reporting System (FAERS)...
Patient-centered pharmacovigilance: priority actions from the inherited bleeding disorders community [0.03%]
以患者为中心的药物警戒：来自遗传性出血性疾病社区的优先行动事项
Fiona Robinson,Sonji Wilkes,Nathan Schaefer et al.
Fiona Robinson et al.
Pharmacovigilance, the science and practice of monitoring the effects of medicinals and their safety, is the responsibility of all stakeholders involved in the development, manufacture, regulation, distribution, prescription, and use of dru...
Development of a checklist for the assessment of pharmacovigilance guidelines in Southern Africa: a document review [0.03%]
在南部非洲制定药品警戒指南评估检查清单的开发：文件审查
Nokuthula L Makhene,Hanlie Steyn,Martine Vorster et al.
Nokuthula L Makhene et al.
Introduction: National regulatory systems in Southern Africa reflect various stages of maturity, and pharmacovigilance (PV) practices are not aligned. In the absence of guidance for formulating PV guidelines in Southern A...